Physician profile
Carlo E Gopez
NPI 1578770004
$8,729.58
in general payments reported to CMS, 2019-2025
42 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 96% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $1,280 · 2021: $1,153 · 2022: $1,201 · 2023: $1,202 · 2024: $1,331 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,657.88 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,153.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $821.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $755.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $743.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.25 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $602.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $495.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $372.87 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.79 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $314.16 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $289.99 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $241.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2021-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $210.98 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $158.27 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlo Gopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.